Current and emerging treatment options for ANCA-associated vasculitis: Potential role of belimumab and other BAFF/APRIL targeting agents

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 333-347

  Lenert, Aleksander ^a   Lenert, Petar ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

A proliferation inducing ligand; Antineutrophil Cytoplasmic antibody associated vasculitis; B cells; B cell activating factor of the TNF family; Granulomatosis with polyangiitis; Microscopic polyangiitis

Indexed keywords

APRIL PROTEIN; ATACICEPT; AZATHIOPRINE; B CELL ACTIVATING FACTOR; BELIMUMAB; BLISIBIMOD; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PLACEBO; PREDNISONE; RITUXIMAB; TABALUMAB; TUMOR NECROSIS FACTOR ALPHA; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; TNFSF13 PROTEIN, HUMAN; TNFSF13B PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLERGY; ANCA ASSOCIATED VASCULITIS; ANTIBODY PRODUCTION; ANTIBODY TITER; AORTA ARCH SYNDROME; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BEHCET DISEASE; BLADDER CANCER; BONE MARROW TOXICITY; BRAIN VASCULITIS; CHURG STRAUSS SYNDROME; CRYOGLOBULINEMIA; CYTOKINE RELEASE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; GIANT CELL ARTERITIS; HEPATITIS C; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFERTILITY; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MEMBRANOUS GLOMERULONEPHRITIS; MICROSCOPIC POLYANGIITIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NON MELANOMA SKIN CANCER; NONHUMAN; OPTIC NEURITIS; PLASMAPHERESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RELAPSE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE ACTIVATION; VASCULITIS; WALDENSTROEM MACROGLOBULINEMIA; WEGENER GRANULOMATOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; DRUG DEVELOPMENT; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL, HUMANIZED; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; DRUG DISCOVERY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 84920916712     PISSN: 11778881     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S67264     Document Type: Review

References (96)

1. Kallenberg CGM. Advances in pathogenesis and treatment of ANCAassociated vasculitis. Discov Med. 2014;18(99):195-201.
2. Tarzi RM, Pusey CD. Current and future prospects in the management of granulomatosis with polyangiitis (Wegener’s granulomatosis). Ther Clin Risk Manag. 2014;10:279-293.
3. Lenert P, Icardi M, Dahmoush L. ANA (+) ANCA (+) systemic vasculitis associated with the use of minocycline: case-based review. Clin Rheumatol. 2013;32(7):1099-1106.
4. Zhao Y, Lutalo PM, Thomas JE, et al. Circulating T follicular helper cell and regulatory T cell frequencies are influenced by B-cell depletion in patients with granulomatosis with polyangiitis. Rheumatology (Oxford). 2014;53(4):621-630.
5. Abdulahad WH, Lepse N, Stegeman CA, et al. Increased frequency of circulating IL-21 producing Th-cells in patients with granulomatosis with polyangiitis (GPA). Arthritis Res Ther. 2013;15(3):R70.
6. Wilde B, Thewissen M, Damoiseaux J, et al. Regulatory B cells in ANCAassociated vasculitis. Ann Rheum Dis. 2013;72(8):1416-1419.
7. Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367(3):214-223.
8. Fauci AS, Wolff SM. Wegener’s granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore). 1973;52(6):535-561.
9. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116(6):488-498.
10. Little MA, Nightingale P, Verburgh CA, et al; European Vasculitis Study (EUVAS) Group. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis. 2010;69(6):1036-1043.
11. Jayne DR, Gaskin G, Rasmussen N, et al; European Vasculitis Study Group. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18(7):2180-2188.
12. Stone JH, Merkel PA, Spiera R, et al; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-232.
13. Jones RB, Tervaert JW, Hauser T, et al; European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211-220.
14. Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med. 2005;352(4):351-361.
15. Golbin JM, Specks U. Targeting B lymphocytes as therapy for ANCA-associated vasculitis. Rheum Dis Clin North Am. 2007;33(4): 741-754.
16. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum. 2012;64(9):3043-3051.
17. Pagnoux C, Mahr A, Hamidou MA, et al; French Vasculitis Study Group. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359(26):2790-2803.
18. Metzler C, Miehle N, Manger K, et al; German Network of Rheumatic Diseases. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener’s granulomatosis. Rheumatology (Oxford). 2007;46(7):1087-1091.
19. Hiemstra TF, Walsh M, Mahr A, et al; European Vasculitis Study Group (EUVAS). Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010;304(21):2381-2388.
20. Holle JU, Dubrau C, Herlyn K, et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener’s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis. 2012;71(3):327-333.
21. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprimsulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996;335(1):16-20.
22. Langford CA, Sneller MC, Hallahan CW, et al. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener’s granulomatosis. Arthritis Rheum. 1996;39(10):1754-1760.
23. Hoffman GS, Thomas-Golbanov CK, Chan J, Akst LM, Eliachar I. Treatment of subglottic stenosis, due to Wegener’s granulomatosis, with intralesional corticosteroids and dilation. J Rheumatol. 2003;30(5):1017-1021.
24. Hernández-Rodríguez J, Hoffman GS, Koening CL. Surgical interventions and local therapy for Wegener’s granulomatosis. Curr Opin Rheumatol. 2010;22(1):29-36.
25. Walsh M, Flossmann O, Berden A, et al; European Vasculitis Study Group. Risk factors for relapse of antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum. 2012;64(2):542-548.
26. Guillevin L, Pagnoux C, Karras A, et al; French Vasculitis Study Group. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771-1780.
27. Mackay F, Schneider P, Rennert P, Browning J. BAFF and APRIL: a tutorial on B cell survival. Annu Rev Immunol. 2003;21:231-264.
28. Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B-cell growth. J Exp Med. 1999;189(11):1747-1756.
29. Schiemann B, Gommerman JL, Vora K, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science. 2001;293(5537):2111-2114.
30. Bossen C, Tardivel A, Willen L, et al. Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and antibody responses. Eur J Immunol. 2011;41(3):787-797.
31. Rauch M, Tussiwand R, Bosco N, Rolink AG. Crucial role for BAFFBAFF-R signaling in the survival and maintenance of mature B cells. PLoS One. 2009;4(5):e5456.
32. Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F. The BAFF/APRIL system: emerging functions beyond B-cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013;24(3):203-215.
33. Baker KP. BLys-an essential survival factor for B cells: basic biology, links to pathology and therapeutic target. Autoimmun Rev. 2004;3(5):368-375.
34. Scapini P, Nardelli B, Nadali G, et al. G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med. 2003;197(3):297-302.
35. Ota M, Duong BH, Torkamani A, et al. Regulation of the B-cell receptor repertoire and self-reactivity by BAFF. J Immunol. 2010;185(7): 4128-4136.
36. Thien M, Phan TG, Gardam S, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004;20(6):785-798.
37. Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999;190(11):1697-1710.
38. Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000;404(6781):995-999.
39. Jacob CO, Pricop L, Putterman C, et al. Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. J Immunol. 2006; 177(4):2671-2680.
40. Jacob N, Guo S, Mathian A, et al. B-cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice. J Immunol. 2011;186(8):4984-4993.
41. Warnatz K, Salzer U, Rizzi M, et al. B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc Natl Acad Sci U S A. 2009;106(33):13945-13950.
42. Zhang J, Roschke V, Baker KP, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol. 2001; 166(1):6-10.
43. Mariette X, Roux S, Zhang J, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren’s syndrome. Ann Rheum Dis. 2003;62(2):168-171.
44. Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BLyS overexpression and altered B-cell differentiation with Sjögren’s syndrome. J Clin Invest. 2002;109(1):59-68.
45. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001;44(6):1313-1319.
46. Tan SM, Xu D, Roschke V, et al. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum. 2003;48(4):982-992.
47. Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10(6):365-373.
48. Liu Z, Davidson A. BAFF inhibition: a new class of drugs for the treatment of autoimmunity. Exp Cell Res. 2011;317(9):1270-1277.
49. Md Yusof MY, Vital EM, Emery P. B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress. Expert Rev Clin Immunol. 2013;9(8):761-772.
50. Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58(8):2453-2459.
51. Kreuzaler M, Rauch M, Salzer U, et al. Soluble BAFF levels inversely correlate with peripheral B-cell numbers and the expression of BAFF receptors. J Immunol. 2012;188(1):497-503.
52. Falk RJ, Jennette JC. ANCA are pathogenic-oh yes they are! J Am Soc Nephrol. 2002;13(7):1977-1979.
53. Holden NJ, Williams JM, Morgan MD, et al. ANCA-stimulated neutrophils release BLyS and promote B-cell survival: a clinically relevant cellular process. Ann Rheum Dis. 2011;70(12):2229-2233.
54. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002;110(7):955-963.
55. Bansal PJ, Tobin MC. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol. 2004;93(4):398-401.
56. Slot MC, Tervaert JW, Boomsma MM, Stegeman CA. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum. 2004;51(2):269-273.
57. Voswinkel J, Müller A, Lamprecht P. Is PR3-ANCA formation initiated in Wegener’s granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production. Ann N Y Acad Sci. 2005;1051:12-19.
58. Nogueira E, Hamour S, Sawant D, et al. Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis. Nephrol Dial Transplant. 2010;25(7): 2209-2217.
59. Edberg JC, Zhou T, Aksi K, et al. Levels of circulating B lymphocyte stimulator (BLys) are elevated in patients with Wegener’s granulomatosis (abstract). Kidney Blood Press Res. 2004;26:256.
60. Krumbholz M, Specks U, Wick M, Kalled SL, Jenne D, Meinl E. BAFF is elevated in serum of patients with Wegener’s granulomatosis. J Autoimmun. 2005;25(4):298-302.
61. Kawasaki A, Tsuchiya N, Fukuzawa T, Hashimoto H, Tokunaga K. Analysis on the association of human BLys (BAFF, TNFSF113B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun. 2002;3(7):424-429.
62. Bader L, Koldingsnes W, Nossent J. B-lymphocyte activating factor levels are increased in patients with Wegener’s granulomatosis and inversely correlated with ANCA titer. Clin Rheumatol. 2010;29(9): 1031-1035.
63. Sanders JS, Huitma MG, Kallenberg CG, Stegeman CA. Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B-cell activator of the tumor necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapse. Ann Rheum Dis. 2006;65(11):1484-1489.
64. Zhao Y, Odell E, Choong LM, et al. Granulomatosis with polyangiitis involves sustained mucosal inflammation that is rich in B-cell survival factors and autoantigen. Rheumatology (Oxford). 2012;51(9): 1580-1586.
65. Schneeweis C, Rafalowicz M, Feist E, et al. Increased levels of BLyS and sVCAM-1 in anti-neutrophil cytoplasmatic antibody (ANCA) associated vasculitides (AAV). Clin Exp Rheumatol. 2010;28(1 suppl 57): 62-66.
66. Xin G, Chen M, Su Y, Xu LX, Zhao MH, Li KS. Serum B-cell activating factor in myeloperoxidase-antineutrophil cytoplasmic antibodiesassociated vasculitis. Am J Med Sci. 2014;348(1):25-29.
67. Nagai M, Hirayama K, Ebihara I, Shimohata H, Kobayashi M, Koyama A. Serum levels of BAFF and APRIL in myeloperoxidase anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis: association with disease activity. Nephron Clin Pract. 2011;118(4):c339-c345.
68. Nishino Y, Tamai M, Kawakami A, et al. Serum levels of BAFF for assessing the disease activity of Takayasu arteritis. Clin Exp Rheumatol. 2010;28(1 suppl 57):14-17.
69. van der Geest KS, Abdulahad WH, Chalan P, et al. Disturbed B-cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica. Arthritis Rheumatol. 2014;66(7):1927-1938.
70. Hamzaoui K, Houman H, Hentati F, Hamzaoui A. BAFF is up-regulated in central nervous system of neuro-Behçet’s disease. J Neuroimmunol. 2008;200(1-2):111-114.
71. Hamzaoui K, Houman H, Ben Dhifallah I, Kamoun M, Hamzaoui A. Serum BAFF levels and skin mRNA expression in patients with Behçet’s disease. Clin Exp Rheumatol. 2008;26(4 suppl 50):S64-S71.
72. Gheita TA, Raafat H, Khalil H, Hussein H. Serum level of APRIL/ BLyS in Behçet’s disease patients: clinical significance in uveitis and disease activity. Mod Rheumatol. 2013;23(3):542-546.
73. Sumita Y, Murakawa Y, Sugiura T, Wada Y, Nagai A, Yamaguchi S. Elevated BAFF levels in the cerebrospinal fluid of patients with neuroBehçet’s disease: BAFF is correlated with progressive dementia and psychosis. Scand J Immunol. 2012;75(6):633-640.
74. Yoshida S, Sakurai Y, Takeda T, Fukuda K. Changes in BAFF/APRIL levels in a 2-year-old girl with Kawasaki disease refractory to intravenous immunoglobulin therapy. J Investig Allergol Clin Immunol. 2013; 23(1):52-53.
75. Park SJ, Shin JI. Interleukin-17 and B-cell-activating factor in Kawasaki disease and juvenile systemic lupus erythematosus. Lupus. 2012;21(11): 1260.
76. Gragnani L, Piluso A, Giannini C, et al. Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcγ receptors. Arthritis Rheum. 2011;63(5): 1446-1451.
77. Fabris M, Quartuccio L, Sacco S, et al. B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection. Rheumatology (Oxford). 2007;46(1):37-43. Dovepress
78. Vallerskog T, Heimbürger M, Gunnarsson I, et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther. 2006; 8(6):R167.
79. Pollard RP, Abdulahad WH, Vissink A, et al. Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren’s syndrome: data from a placebo-controlled clinical trial. Ann Rheum Dis. 2013;72(1):146-148.
80. Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48(11): 3253-3265.
81. Jacobi AM, Huang W, Wang T, et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2010;62(1):201-210.
82. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61(9): 1143-1151.
83. Navarra SV, Guzmán RM, Gallacher AE, et al; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721-731.
84. Furie R, Petri M, Zamani O, et al; BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918-3930.
85. Wallace DJ, Navarra S, Petri MA, et al; BLISS-52 and -76, and LBSL02 Study Groups. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 2013;22(2):144-154.
86. Stohl W, Hiepe F, Latinis KM, et al; BLISS-52 Study Group; BLISS-76 Study Group. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B-cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(7):2328-2337.
87. Askanase AD, Yazdany J, Molta CT. Post-marketing experiences with belimumab in the treatment of SLE patients. Rheum Dis Clin North Am. 2014;40(3):507-517.
88. Genovese MC, Bojin S, Biagini IM, et al. Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naïve to biologic therapy: a phase II, randomized, placebo-controlled trial. Arthritis Rheum. 2013;65(4):880-889.
89. Ginzler EM, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther. 2012;14(1):R33.
90. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol. 2002;3(10):944-950.
91. Lenert P, Brummel R, Field EH, Ashman RF. TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J Clin Immunol. 2005;25(1):29-40.
92. Genovese MC, Kinnman N, de La Bourdonnaye G, Pena Rossi C, Tak PP. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum. 2011;63(7):1793-1803.
93. van Vollenhoven RF, Kinnman N, Vincent E, Wax S, Bathon J. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum. 2011;63(7):1782-1792.
94. Huard B, Tran NL, Benkhoucha M, Manzin-Lorenzi C, Santiago-Raber ML. Selective APRIL blockade delays systemic lupus erythematosus in mouse. PLoS One. 2012;7(2):e31837.
95. Roescher N, Vosters JL, Alsaleh G, et al. Targeting the splicing of mRNA in autoimmune diseases: BAFF inhibition in Sjögren’s syndrome as a proof of concept. Mol Ther. 2014;22(4):821-827.
96. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the research on adverse drug events and reports (RADAR) Project. Lancet Oncol. 2009;10(8):816-824.